Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Abemaciclib (Primary) ; Caffeine; Dextromethorphan; Midazolam; Warfarin
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 31 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 May 2018.
- 18 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Sep 2017.
- 18 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2017.